pTTL (personalised tumour-trained lymphocytes) is a personalised cell therapy based on the patient’s own T cells, extracted from regional lymph nodes and trained to recognise tumour-specific neoantigens. The treatment is currently being evaluated in an ongoing Phase I/IIa clinical trial in patients with advanced colorectal cancer.

EpiTCer^®, Neogap’s proprietary technology, plays a central role in the development of pTTL. By mimicking natural antigen presentation, it delivers selected neoantigens to the immune system. It is also used to develop potency assays – functional tests that assess the therapy’s ability to trigger a tumour-directed immune response.

“The EpiTCer^® technology is very powerful, as it not only enables efficient delivery of neoantigens to the immune system and selective expansion of tumour-specific T cells, but also provides us with the tools to functionally assess the potency of our therapy. This combination makes Neogap’s approach unique within cell therapy,” says Ola Nilsson, Head of Neoantigen Production, Development & Clinical Processing at Neogap Therapeutics.

“Neoantigen Summit is a key international forum for demonstrating how we bridge technological innovation with clinical application – and to contribute our perspectives to the global conversation on the future of cancer treatment.”

Neoantigen Summit Europe is a leading international conference focused on neoantigen-based therapies, bringing together researchers, clinicians and industry leaders from around the world.

The conference will be held in Amsterdam on 24–26 June 2025. Ola Nilsson is scheduled to speak on 26 June at 11:30. For registration and program details, visit the event website: https://neoantigen-summit.com/.

Project reference number: 190185439 – NEOpTTL. Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.

For more information, please contact:
Samuel Svensson, CEO
Email: samuel.svensson@neogap.se
Phone: +46 733 54 21 94

About Neogap Therapeutics
Neogap Therapeutics is a Swedish clinical-stage biotechnology company focused on developing personalised cancer immunotherapy using the patient’s own cells. The therapy is based on the company’s two technologies PIOR^® and EpiTCer^®. PIOR^® is sophisticated software that uses DNA sequencing data from the patient and machine learning algorithms to select tumour-specific mutations. Then, EpiTCer^® is used to multiply T cells that can recognize and attack the selected tumor-specific targets. Neogap is located at Cancer Center Karolinska in Stockholm. To learn more about Neogap and its cutting-edge research, please visit neogap.se and follow Neogap on LinkedIn.